TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32325491

Group type: EXPERIMENTAL
Intervention: Mature neutrophils at diagnosis
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Mature neutrophils
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Depletion of mature neutrophils
Number of subjects: 267
Study: 35024932

Group type: EXPERIMENTAL
Intervention: Underwater cold snare polypectomy (U-CSP)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Conventional cold snare polypectomy (C-CSP)
Number of subjects: 110
Study: 34231351

Group type: EXPERIMENTAL
Intervention: CMO pharmaceutical care model-based intervention
Number of subjects: 39

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 39
Study: 32342893

Group type: EXPERIMENTAL
Intervention: Seat pan angle of 40° and backrest angle of 155°
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Seat pan angles of 20°, 30°, 40° and backrest angles of 145°, 155°, 165°
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Combination of 165° backrest angle with a seat pan of 20°
Number of subjects: 23
Study: 32191071

Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking with health goal (EFT-health goal)
Number of subjects: 444

Group type: COMPARATOR
Intervention: Episodic Future Thinking without health goal (EFT-general)
Number of subjects: 444

Group type: COMPARATOR
Intervention: Episodic Recent Thinking with health goal (ERT-health goal)
Number of subjects: 444

Group type: COMPARATOR
Intervention: Episodic Recent Thinking without health goal (ERT-general)
Number of subjects: 444
Study: 32282255

Group type: EXPERIMENTAL
Intervention: PFMT+KT
Number of subjects: 0

Group type: COMPARATOR
Intervention: PFMT+ST
Number of subjects: 0
Study: 32979708

Group type: EXPERIMENTAL
Intervention: Soybean (Soygan 500 mg capsule)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (Omega-rex 1000 mg soft gel)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 35218203

Group type: EXPERIMENTAL
Intervention: Eptinezumab 100 mg
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Eptinezumab 300 mg
Number of subjects: 385

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 385
Study: 34026336

Group type: EXPERIMENTAL
Intervention: Gemcitabine + Docetaxel (GD)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Docetaxel alone
Number of subjects: 237
Study: 35737597

Group type: EXPERIMENTAL
Intervention: Palmitoylethanolamide 600 mg plus lithium and risperidone 3 mg
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 34139228

Group type: EXPERIMENTAL
Intervention: Nomogram developed using CT parameters
Number of subjects: 1001
Study: 32015513

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC)
Number of subjects: 488
Study: 34714125

Group type: EXPERIMENTAL
Intervention: Oral care with mother's own milk (MOM)
Number of subjects: 110
Study: 32772215

Group type: EXPERIMENTAL
Intervention: CAF plus CMX
Number of subjects: 24

Group type: COMPARATOR
Intervention: CAF alone
Number of subjects: 24
Study: 35363574

Group type: EXPERIMENTAL
Intervention: 90-day multipurpose prevention technology (MPT) intravaginal ring (IVR)
Number of subjects: 47
Study: 33783495

Group type: EXPERIMENTAL
Intervention: Streamlined ART care (rapid ART start, visit spacing, flexible clinic hours, welcoming environment)
Number of subjects: 13266

Group type: EXPERIMENTAL
Intervention: Streamlined ART care
Number of subjects: 13266

Group type: COMPARATOR
Intervention: Control (standard treatment model)
Number of subjects: 13266
Study: 35413022

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection (defined as COVID-19 clinical diagnosis or presence of SARS-CoV-2 IgG/IgA antibodies)
Number of subjects: 2464

Group type: EXPERIMENTAL
Intervention: Asymptomatic SARS-CoV-2 infection
Number of subjects: 2464

Group type: EXPERIMENTAL
Intervention: Symptomatic COVID-19
Number of subjects: 2464

Group type: EXPERIMENTAL
Intervention: CD4 counts and HIV viral suppression rates
Number of subjects: 2464
Study: 33705167

Group type: EXPERIMENTAL
Intervention: Modular cognitive behavioral therapy (CBT)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Enhanced standard community treatment (ESCT)
Number of subjects: 107
Study: 32033527

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (50,000 IU/week for 8 weeks)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 33441831

Group type: EXPERIMENTAL
Intervention: Transcriptomic analysis of female P. edita
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcriptomic analysis of male P. edita
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Validation of transcriptomic data by qRT‐PCR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Identification of simple sequence repeats (SSRs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparative analysis of sex-related genes and pathways
Number of subjects: 0
Study: 33021870

Group type: EXPERIMENTAL
Intervention: Ixazomib
Number of subjects: 706

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 706
Study: 35225460

Group type: EXPERIMENTAL
Intervention: 200 ml ONS twice a day
Number of subjects: 58

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 58
Study: 32660299

Group type: EXPERIMENTAL
Intervention: Adjunctive low-dose transdermal testosterone cream
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 35833539

Group type: EXPERIMENTAL
Intervention: Equine‐derived collagenated xenogeneic bone blocks (CXBB)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Autogenous bone block (ABB)
Number of subjects: 64
Study: 34980307

Group type: EXPERIMENTAL
Intervention: Early off-bed mobility (using shift machine, off-bed sitting, and walking aids)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Early off-bed mobility
Number of subjects: 266
Study: 36301169

Group type: EXPERIMENTAL
Intervention: DCKEBS+acupuncture
Number of subjects: 147

Group type: COMPARATOR
Intervention: DCKEBS
Number of subjects: 147

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 147
Study: 34535548

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine with 5 mg dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.5% ropivacaine (control)
Number of subjects: 0
Study: 36166273

Group type: EXPERIMENTAL
Intervention: Pedometer-based program to improve physical activity (PA) over 3 months
Number of subjects: 59
Study: 34198131

Group type: EXPERIMENTAL
Intervention: Nicotine (2-mg lozenge)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 33264172

Group type: EXPERIMENTAL
Intervention: Left atrial appendage occlusion (LAAO)
Number of subjects: 0
Study: 616521239

Group type: EXPERIMENTAL
Intervention: TACE and bevacizumab
Number of subjects: 22

Group type: COMPARATOR
Intervention: TACE and placebo
Number of subjects: 22
Study: 34352069

Group type: EXPERIMENTAL
Intervention: filgotinib 200 mg once daily for 12 weeks
Number of subjects: 116

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 116
Study: 33148476

Group type: EXPERIMENTAL
Intervention: Total Ankle Replacement (TAA)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Ankle Arthrodesis (AA)
Number of subjects: 39
Study: 36178832

Group type: EXPERIMENTAL
Intervention: Pharmacist-delivered one-on-one feedback to GPs and electronic tick-box for GPs to select action for each patient.
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Engagement with GPs in the intervention group.
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Sending letters to patients with high-risk prescribing.
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: General engagement and participation in the trial.
Number of subjects: 39
Study: 33704969

Group type: EXPERIMENTAL
Intervention: Parent-focused literacy intervention (Reach Out and Read)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Baseline (preintervention) measurements
Number of subjects: 38
Study: 35473436

Group type: EXPERIMENTAL
Intervention: Evening performance (19:00 h)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Morning performance (9:00 h)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Chronotype
Number of subjects: 15
Study: 32679839

Group type: EXPERIMENTAL
Intervention: Forest video
Number of subjects: 0

Group type: COMPARATOR
Intervention: Urban video (Control)
Number of subjects: 0
Study: 33271604

Group type: EXPERIMENTAL
Intervention: Diagnose-and-leave-in strategy for diminutive rectosigmoid polyps
Number of subjects: 256
Study: 33693653

Group type: EXPERIMENTAL
Intervention: Women with PCOS
Number of subjects: 9508

Group type: COMPARATOR
Intervention: Women without PCOS
Number of subjects: 9508

Group type: EXPERIMENTAL
Intervention: Obese women with PCOS
Number of subjects: 9508

Group type: COMPARATOR
Intervention: Lean women with PCOS
Number of subjects: 9508
Study: 32787371

Group type: EXPERIMENTAL
Intervention: Selective anticoagulation group (SAG)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Conventional anticoagulation group (CAG)
Number of subjects: 197
Study: 34308903

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 130
Study: 32285979

Group type: EXPERIMENTAL
Intervention: Nicotine gum (2 mg)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study: 34019513

Group type: EXPERIMENTAL
Intervention: Surgical treatment of migraine headaches
Number of subjects: 0
Study: 615261596

Group type: EXPERIMENTAL
Intervention: anodal tDCS
Number of subjects: 14

Group type: COMPARATOR
Intervention: sham
Number of subjects: 14
Study: 34245336

Group type: EXPERIMENTAL
Intervention: trastuzumab + docetaxel
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: bevacizumab
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: trastuzumab
Number of subjects: 86
Study: 34758056

Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA) compound filling plus mesotherapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Botulinum Toxin A (BTX-A) injection
Number of subjects: 48
Study: 34508021

Group type: EXPERIMENTAL
Intervention: Computer-based lumbar disc surgery discharge training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine discharge training in the ward (Control)
Number of subjects: 60
Study: 36484803

Group type: EXPERIMENTAL
Intervention: Test methotrexate tablet (2.5 mg) under fasting conditions
Number of subjects: 52

Group type: COMPARATOR
Intervention: Reference methotrexate tablet (2.5 mg) under fed conditions
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Test and reference methotrexate tablets (2.5 mg)
Number of subjects: 52
Study: 33203966

Group type: EXPERIMENTAL
Intervention: AACQ
Number of subjects: 264

Group type: COMPARATOR
Intervention: TQ
Number of subjects: 264
Study: 32389679

Group type: EXPERIMENTAL
Intervention: 20-month Sun Safe Schools intervention (N = 58)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Minimal informational control condition (N = 60)
Number of subjects: 118
Study: 35762322

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 5988

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5988
Study: 34639438

Group type: EXPERIMENTAL
Intervention: Hamstring Relaxation Program (HR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (Electrotherapy)
Number of subjects: 30
Study: 35752793

Group type: EXPERIMENTAL
Intervention: New Chewing Problem Directory (CPD)
Number of subjects: 537
Study: 33314079

Group type: EXPERIMENTAL
Intervention: Eptinezumab 100 mg
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Eptinezumab 300 mg
Number of subjects: 431

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 431
Study: 34748017

Group type: EXPERIMENTAL
Intervention: Mouth-formed OPRO® Gold Braces (MG2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Custom-made laboratory constructed mouthguard (MG1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pre-fabricated Shock Doctor® Single Brace (MG3)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Overall preference
Number of subjects: 30
Study: 33446083

Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 300
Study: 32524654

Group type: EXPERIMENTAL
Intervention: Specialist-optimized image without zoom
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Reader-optimized measurement (ROM) images without zoom
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Specialist-optimized image with zoom
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Region of interest (ROI) with zoom
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intra-rater agreement between readers
Number of subjects: 16
Study: 35277166

Group type: EXPERIMENTAL
Intervention: 0.375% ropivacaine with 1 µg/kg dexmedetomidine in 20 ml for ESPB (Group E)
Number of subjects: 120

Group type: COMPARATOR
Intervention: 0.375% ropivacaine for ESPB (Group C)
Number of subjects: 120
Study: 34583763

Group type: EXPERIMENTAL
Intervention: Low-normal oxygen, carbon dioxide, and mean arterial blood pressure (MAP) targets for 48 hours
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: High-normal oxygen, carbon dioxide, and mean arterial blood pressure (MAP) targets for 48 hours
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Impaired CVR
Number of subjects: 120
Study: 36165691

Group type: EXPERIMENTAL
Intervention: Primary Ross procedure
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Secondary Ross procedure
Number of subjects: 158
Study: 33826709

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 or 300 mg
Number of subjects: 599
Study: 36083489

Group type: EXPERIMENTAL
Intervention: Shugan Jieyu capsule
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 34674843

Group type: EXPERIMENTAL
Intervention: Intravenous piperacillin/tazobactam for 24–48 h followed by 10 days of oral ciprofloxacin/metronidazole
Number of subjects: 39

Group type: COMPARATOR
Intervention: Appendectomy
Number of subjects: 39
Study: 34226192

Group type: EXPERIMENTAL
Intervention: Plaster cast
Number of subjects: 669

Group type: COMPARATOR
Intervention: Removable brace
Number of subjects: 669
Study: 35779616

Group type: EXPERIMENTAL
Intervention: PAPR with PM and VOCs filter
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PAPR with PM filter
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham filter (no filtration)
Number of subjects: 40
Study: 34161745

Group type: EXPERIMENTAL
Intervention: Nitrate supplement (0.11 mmol nitrate/kg as beetroot juice)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 35377427

Group type: COMPARATOR
Intervention: Handgun carrying in the past 12 months
Number of subjects: 2002

Group type: COMPARATOR
Intervention: Latent class growth analysis of handgun carrying trajectories
Number of subjects: 2002

Group type: COMPARATOR
Intervention: Age at initiation of handgun carrying
Number of subjects: 2002

Group type: COMPARATOR
Intervention: Frequency of carrying by age 26
Number of subjects: 2002
Study: 34108160

Group type: EXPERIMENTAL
Intervention: Shonjibon Cash and Counselling (SCC) Trial combining nutrition counselling and unconditional cash transfer delivered on a mobile platform
Number of subjects: 2840

Group type: EXPERIMENTAL
Intervention: Nutrition behaviour change communications (BCCs) and cash transfers
Number of subjects: 2840
Study: 32056088

Group type: EXPERIMENTAL
Intervention: TAVR-LBBB patients with septal flash (LBBBTAVR+SF)
Number of subjects: 25

Group type: COMPARATOR
Intervention: LBBBTAVR+SF
Number of subjects: 25

Group type: COMPARATOR
Intervention: LBBBSF+PEF
Number of subjects: 25

Group type: COMPARATOR
Intervention: LBBBSF+REF
Number of subjects: 25
Study: 36418988

Group type: EXPERIMENTAL
Intervention: mobile-enhanced Family Integrated Care (mFICare)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Family-Centered Care (FCC)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: mFICare (per-protocol analysis)
Number of subjects: 253
Study: 32814310

Group type: EXPERIMENTAL
Intervention: WEBA ergometer
Number of subjects: 6

Group type: COMPARATOR
Intervention: Dansprint
Number of subjects: 6
Study: 35751597

Group type: EXPERIMENTAL
Intervention: Maternal inattention symptoms
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Maternal hyperactivity symptoms
Number of subjects: 80
Study: 32842203

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor combined with ranitidine
Number of subjects: 70
Study: 34592421

Group type: EXPERIMENTAL
Intervention: Normal paced breathing (0.25 Hz)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Slow paced breathing (0.1 Hz)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Su-soku practice
Number of subjects: 30
Study: 36016996

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural analgesia (CSEA)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Epidural analgesia (EA)
Number of subjects: 233
Study: 34581796

Group type: EXPERIMENTAL
Intervention: Sucrose (75 g)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Sucralose (individually sweetness matched)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Sucralose vs Sucrose
Number of subjects: 74
Study: 34388414

Group type: EXPERIMENTAL
Intervention: Intravenous thiamine (200 mg every 12 hours for up to 14 doses)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 90
Study: 32220359

Group type: EXPERIMENTAL
Intervention: Soy-enriched fat modified diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (fat modified diet)
Number of subjects: 0
Study: 35840996

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Yi Jin Jing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 34518377

Group type: EXPERIMENTAL
Intervention: Bihormonal bionic pancreas (BHBP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 10
Study: 35792253

Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT) on the tongue surface
Number of subjects: 24
Study: 35653229

Group type: EXPERIMENTAL
Intervention: AZD8233 antisense oligonucleotide
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 32745878

Group type: COMPARATOR
Intervention: Conventional hand weeding (no weedicide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-emergence weedicide pendimethalin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-emergence weedicide imazethapyr for soybean
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weedicide atrazine for maize
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soil depth
Number of subjects: 0
Study: 32614422

Group type: EXPERIMENTAL
Intervention: AF episode duration of less than 24 hours
Number of subjects: 346

Group type: COMPARATOR
Intervention: AF episode duration of longer than 24 hours
Number of subjects: 346
Study: 37183246

Group type: EXPERIMENTAL
Intervention: Community-led arsenic mitigation program with point-of-use (POU) arsenic filters installed at baseline and followed for 2 years.
Number of subjects: 0
Study: 34397680

Group type: EXPERIMENTAL
Intervention: Baduanjin exercise
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 32815803

Group type: EXPERIMENTAL
Intervention: Preoperative opioid education
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control cohort (no preoperative opioid education)
Number of subjects: 100
Study: 34915980

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Mediterranean lifestyle
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: < 5% weight loss group
Number of subjects: 180

Group type: COMPARATOR
Intervention: WS/GG (weight-stable/gain)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: ≥ 10% weight loss group
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: ≥ 5% weight loss
Number of subjects: 180
Study: 34663391

Group type: EXPERIMENTAL
Intervention: Ultrasound group
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 117
Study: 32799851

Group type: EXPERIMENTAL
Intervention: Single high-molecular-weight hyaluronic acid (HMW-HA) injection (Arthromac)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Triple low-molecular-weight hyaluronic acid (LMW-HA) injections (Hyalgan)
Number of subjects: 90
Study: 36353351

Group type: EXPERIMENTAL
Intervention: Cup placement in true acetabulum
Number of subjects: 46

Group type: COMPARATOR
Intervention: Cup placement in false acetabulum
Number of subjects: 46
Study: 33048195

Group type: EXPERIMENTAL
Intervention: Viscoelastic Haemostatic Assays (VHA)
Number of subjects: 396

Group type: COMPARATOR
Intervention: Conventional Coagulation Tests (CCT)
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Viscoelastic Haemostatic Assays (VHA) in TBI subgroup
Number of subjects: 396

Group type: COMPARATOR
Intervention: Conventional Coagulation Tests (CCT) in TBI subgroup
Number of subjects: 396
Study: 34767836

Group type: EXPERIMENTAL
Intervention: Hydrogel
Number of subjects: 18
Study: 34555676

Group type: EXPERIMENTAL
Intervention: Tailored axillary surgery (TAS)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Tailored axillary surgery (TAS) followed by axillary lymph node dissection (ALND)
Number of subjects: 296
Study: 35366867

Group type: EXPERIMENTAL
Intervention: Mobile device app for inhaler education
Number of subjects: 90

Group type: COMPARATOR
Intervention: Manufacturer's instruction guide
Number of subjects: 90
Study: 33558662

Group type: EXPERIMENTAL
Intervention: Cryotherapy + GM-CSF (Treatment group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cryotherapy alone (Control group)
Number of subjects: 20
Study: 33417216

Group type: COMPARATOR
Intervention: Orally administered plasmalogens (Pls) for 24 weeks in MCI and PD, and 12 weeks in moderate and severe AD.
Number of subjects: 361

Group type: COMPARATOR
Intervention: Orally administered plasmalogens (Pls) for 12 weeks in moderate and severe AD.
Number of subjects: 361

Group type: COMPARATOR
Intervention: Orally administered plasmalogens (Pls) for 24 weeks in PD.
Number of subjects: 361
Study: 36035829

Group type: EXPERIMENTAL
Intervention: Intelligent surgical hole towel
Number of subjects: 1220

Group type: COMPARATOR
Intervention: Control group (disposable ophthalmic single-port operation cloth)
Number of subjects: 1220
Study: 33184023

Group type: EXPERIMENTAL
Intervention: Serious game (See)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Care-as-usual (CAU)
Number of subjects: 64